FDA outlines plan to be more transparent to industry

New report on transparency asks for public comment

The Food and Drug Administration is undertaking 19 new actions and considering five additional proposed actions as part of its broad effort to improve transparency to regulated industries.

The plans are detailed in a new report, "FDA Transparency Initiative: Improving Transparency to Regulated Industry," posted on the FDA website and published in the Federal Register today.


Related coverage:

FDA task force proposes 21 transparency initiatives

FDA wants ideas for transparency


Public comments are welcome until March 8.

The 19 actions span three major areas of activity. Six pertain to FDA communications, four to the product application review process, two to guideline development, two to the regulations development process and five to the import process.

For example, under a new policy, FDA said that if it receives a question via e-mail about how it operates, it will strive to provide a response within five days. For complex questions, it will acknowledge the inquiry and indicate how long it will take to respond.

FDA also said it would update its online organizational and leadership charts at least quarterly and post copies of any presentations by FDA employees to outside groups at events sponsored or co-sponsored by FDA.

About the Author

Alice Lipowicz is a staff writer covering government 2.0, homeland security and other IT policies for Federal Computer Week.

2014 Rising Star Awards

Help us find the next generation of leaders in federal IT.

Reader comments

Please post your comments here. Comments are moderated, so they may not appear immediately after submitting. We will not post comments that we consider abusive or off-topic.

Please type the letters/numbers you see above